Ceribell
Public neurodiagnostics company using rapid-application EEG hardware and AI seizure-detection software to push brain monitoring closer to the ICU and emergency bedside.
What They Do
Ceribell sells a point-of-care EEG platform that combines disposable headbands, a portable recorder, cloud software, and AI-enabled seizure detection to help hospitals diagnose neurological emergencies without waiting for full conventional EEG setup. The company's initial commercial focus was adult and general acute-care seizure detection, but it has expanded into neonatal and pediatric monitoring with a neonatal headcap and FDA-cleared neonatal Clarity algorithm. Ceribell's business model is provider-facing rather than payer-facing: hospitals adopt the system to speed diagnosis, shorten time to treatment, and reduce dependence on specialist EEG workflows. That makes the company strategically relevant to NICUs because it is extending a broader acute-neuro platform into neonatal care rather than building exclusively for newborns.
Competitive Position
Ceribell competes against conventional EEG infrastructure from incumbents like Natus as well as newer neonatal-focused brain-monitoring startups such as cergenx and neurobell. Its edge is scale: it already has broad hospital commercial traction, FDA-cleared AI seizure detection, and post-IPO capital to fund sales and clinical expansion. The tradeoff is that Ceribell's product was built first for the broader acute-neuro market, so neonatal specialists may still compare it against tools designed more narrowly around newborn workflow and signal interpretation.